These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 33032867)

  • 21. [Cholangiocarcinoma-diagnosis, classification, and molecular alterations].
    Goeppert B
    Pathologe; 2020 Sep; 41(5):488-494. PubMed ID: 32757029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF).
    Neuzillet C; Decraecker M; Larrue H; Ntanda-Nwandji LC; Barbier L; Barge S; Belle A; Chagneau C; Edeline J; Guettier C; Huguet F; Jacques J; Le Bail B; Leblanc S; Lewin M; Malka D; Ronot M; Vendrely V; Vibert É; Bureau C; Bourliere M; Ganne-Carrie N; Blanc JF
    Liver Int; 2024 Oct; 44(10):2517-2537. PubMed ID: 38967424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
    Izquierdo-Sanchez L; Lamarca A; La Casta A; Buettner S; Utpatel K; Klümpen HJ; Adeva J; Vogel A; Lleo A; Fabris L; Ponz-Sarvise M; Brustia R; Cardinale V; Braconi C; Vidili G; Jamieson NB; Macias RI; Jonas JP; Marzioni M; Hołówko W; Folseraas T; Kupčinskas J; Sparchez Z; Krawczyk M; Krupa Ł; Scripcariu V; Grazi GL; Landa-Magdalena A; Ijzermans JN; Evert K; Erdmann JI; López-López F; Saborowski A; Scheiter A; Santos-Laso A; Carpino G; Andersen JB; Marin JJ; Alvaro D; Bujanda L; Forner A; Valle JW; Koerkamp BG; Banales JM
    J Hepatol; 2022 May; 76(5):1109-1121. PubMed ID: 35167909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?
    Sapisochin G; Ivanics T; Heimbach J
    Hepatology; 2022 Feb; 75(2):455-472. PubMed ID: 34859465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
    Ilyas SI; Gores GJ
    Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
    Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
    BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.
    Lurje G; Bednarsch J; Czigany Z; Lurje I; Schlebusch IK; Boecker J; Meister FA; Tacke F; Roderburg C; Den Dulk M; Gaisa NT; Bruners P; Neumann UP
    Eur J Surg Oncol; 2019 Aug; 45(8):1468-1478. PubMed ID: 31053477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New epidemiologic trends in cholangiocarcinoma.
    Pascale A; Rosmorduc O; Duclos-Vallée JC
    Clin Res Hepatol Gastroenterol; 2023 Nov; 47(9):102223. PubMed ID: 37797807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
    Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
    BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.
    Loilome W; Namwat N; Jusakul A; Techasen A; Klanrit P; Phetcharaburanin J; Wangwiwatsin A
    Recent Results Cancer Res; 2023; 219():53-90. PubMed ID: 37660331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of clinical characteristics and mortality risk between patients with cholangiocarcinoma: A retrospective cohort study.
    Liu Y; Wang Y; Yu Y; Luo H; Zhen M; Ren J
    Front Surg; 2022; 9():1037310. PubMed ID: 36873806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for perihilar cholangiocarcinoma: a hospital-based case-control study.
    Lee BS; Cha BH; Park EC; Roh J
    Liver Int; 2015 Mar; 35(3):1048-53. PubMed ID: 24923595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gallbladder and bile duct carcinoma. Biology and pathology].
    Tannapfel A; Wittekind C
    Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucosal-associated invariant T-cell tumor infiltration predicts long-term survival in cholangiocarcinoma.
    Zimmer CL; Filipovic I; Cornillet M; O'Rourke CJ; Berglin L; Jansson H; Sun D; Strauss O; Hertwig L; Johansson H; von Seth E; Sparrelid E; Dias J; Glaumann H; Melum E; Ellis EC; Sandberg JK; Andersen JB; Bergquist A; Björkström NK
    Hepatology; 2022 May; 75(5):1154-1168. PubMed ID: 34719787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers.
    Zhang Y; Ma Z; Li C; Wang C; Jiang W; Chang J; Han S; Lu Z; Shao Z; Wang Y; Wang H; Jiao C; Wang D; Wu X; Shen H; Wang X; Hu Z; Li X
    Nat Commun; 2022 Jun; 13(1):3061. PubMed ID: 35650238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
    Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
    Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventing futile surgery in Intrahepatic and Perihilar cholangiocarcinomas: Can we identify preoperative factors to improve patient selection and optimize outcomes?
    Goel M; Varty GP; Patkar S; Meghana V; Kazi M; Nandy K; Ostwal V; Ramaswamy A; Gala KB; Shetty NS
    Surg Oncol; 2024 Aug; 55():102096. PubMed ID: 38964224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Textbook oncologic outcomes among patients undergoing laparoscopic, robotic and open surgery for intrahepatic and perihilar cholangiocarcinoma.
    Munir MM; Dillhoff M; Tsai S; Pawlik TM
    HPB (Oxford); 2024 Aug; 26(8):1051-1061. PubMed ID: 38825434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
    Wiggers JK; Ruys AT; Groot Koerkamp B; Beuers U; ten Kate FJ; van Gulik TM
    J Gastroenterol Hepatol; 2014 Aug; 29(8):1582-94. PubMed ID: 24787096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.